Thus far, clinical data are limited; a recent case report describes the long-term remission of fusariosis in a patient with acute myelogenous leukemia following the introduction of nivolimab (PD-1 inhibitor) to standard antifungal therapy [220]. This evidence concerns the gene PDCD1 and fusariosis.